Meet Clay Siegall: A Leader and a Talented Researcher
Clay Siegall is the founder as well as the Chief executive officer of Seattle Genetics. Seattle Genetics is a company based in Seattle. It focuses on the development of therapeutic drugs for ailments, which have not yet seen a considerable mortality improvement. He founded the firm in the year 1998. His excellent leadership skills have helped it achieve several mouth-watering achievements in the area of cancer research.
Under the leadership of Dr. Clay Siegall, Settle Genetics has been able to come up with an antibody-drug conjugate. The drug was initially approved by FDA but now has several approved indications. Other than the antibody-drug conjugate, the firm has also developed over 20 drugs. It has also partnered with renowned drug manufacturers such as Genentech, Pfizer, Bayer, and many others.
Clay Siegall helped Seattle Genetics grow from a small startup with a few researchers to one of the most significant players in the field of cancer research. He has good plans for the organization’s future. The company continues to discover more and more drugs. This crystal means that it has a bright future.
How Dr. Clay Siegall Started the Business
Clay Siegall has been interested in medicine as well as the power of technology since he was young. He had the ambition of restoring good health to patients who had minimal chances of surviving. He initially became interested in the cancer treatment while at the university studying zoology. He became more interested in the field research when he saw a family member, who had been diagnosed with cancer suffer during chemotherapy.
He decided to find out whether there were other better ways of treating cancer patients. This is how he came to know radical surgery as well as amputation. He started the company because he wanted to be his own boss and not because he wanted to make a great deal of money.
About Dr. Clay Siegall
Clay Siegall attended the University of Maryland where he acquired a degree in Zoology. Later, he attended George Washington University where he acquired his Ph.D. in genetics. He co-founded the Seattle Genetic Company in the year 1997. He became the president and the Chief Executive Officer of the company in 2000 and 2002 respectively. He also worked at the company as the Executive Vice President from 1997 to 2000. He has about twenty years of experience in the field of cancer research as well as therapeutic drug development.